Bone Marrow Aspirate Concentrate Improves the Early Osseous Integration of Fresh Osteochondral Allografts in the Knee: A Randomized Controlled Trial.

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

36 patients undergoing fresh osteochondral allograft (FOCA) transplantation for focal osteochondral lesions of the knee were randomized to receive bone marrow aspirate concentrate augmentation (BMAC) or no BMAC. The primary outcome was osseous integration assessed on computed tomography using the semiquantitative assessment computed tomography osteochondral allograft scoring system. Other outcomes included graft signal density, cleft formation, cystic changes, intra-articular fragments, International Knee Documentation Committee (IKDC) score, Kujala score, Western Ontario Meniscal Evaluation Tool (WOMET) score, and Tegner activity score. Computed tomography outcomes were assessed at 3, 6, and 12 months, while clinical outcomes were assessed at 6, 12, and 24 months. Overall, BMAC improved osseous integration at the host-graft junction at 3 months, but this advantage was no longer present at 6 or 12 months. Patient-reported outcomes were comparable between groups, suggesting that BMAC may accelerate early graft incorporation without providing superior short-term clinical outcomes.